Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Vaccine + Durvalumab in ES-SCLC
NCT04397003Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2022
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in small cell lung cancer (SCLC), sponsored by Washington University School of Medicine. Primary endpoints: Adverse Events and Vaccine Production Feasibility. Started Mar 2022; status: active, not recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04397003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397003.